Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01673555
Other study ID # 116008
Secondary ID
Status Completed
Phase Phase 1
First received July 12, 2012
Last updated June 7, 2017
Start date May 15, 2012
Est. completion date November 19, 2012

Study information

Verified date June 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers. Healthy subjects will be evaluated using echocardiography to estimate PASP based on the velocity of the tricuspid regurgitant jet. Resting PASP will be assessed under normoxic (room air) conditions, as well as after 30 minutes' exposure to 15% O2 before, during, and after short-term treatment with GSK1278863.


Description:

This is a single-center, randomized, placebo-controlled, single-blinded (subjects and investigators will be blinded, GSK internal personnel will not be blinded) study designed to test whether short-term administration (5 days) of GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers. Approximately 45 healthy subjects with mild-moderate baseline tricuspid regurgitation (sufficient to allow reliable assessment of PASP) will be enrolled into this study and will provide ~15 evaluable subjects in each arm [Placebo, 5 mg, and 100 mg GSK 1278863].


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date November 19, 2012
Est. primary completion date November 19, 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- AST, ALT, alkaline phosphatase and bilirubin less than and equal to 1.5xULN (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).

- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including [medical history, physical examination and laboratory tests]. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk and will not interfere with the study procedures.

- A hemoglobin value at screening between 13.5- 16 g/dL.

- Male subjects between 18 and 55 years of age inclusive, at the time of signing the informed consent.

- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.

- BMII less than and equal to 32 kg/m2

- Single QTcB or QTcF less than 450 msec

- Screening echocardiogram of at least good quality, without clinically significant abnormalities, and with mild-moderate tricuspid regurgitation sufficient for the reliable estimation of PASP, as determined by the echocardiography core laboratory or responsible cardiologist.

- Screening PASP within the normal range under normoxic conditions.

Exclusion Criteria:

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result.

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- A positive pre-study drug/alcohol screen.

- Any history of IV drug abuse.

- A positive test for HIV antibody.

- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 14 drinks for males or greater than 7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.

- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.

- Strong family history of malignancy.

- Subjects with sickle cell trait.

- History of pulmonary hypertension

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GSK1278863
GSK1278863
Placebo
Placebo

Locations

Country Name City State
United States GSK Investigational Site Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Placebo-adjusted change from baseline in PASP (estimated by transthoracic echocardiography) under normoxic conditions following 5 days of GSK1278863 Day 5
Secondary Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions 8 hours after the first dose of study treatment 8 hours Day 1
Secondary Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions following 1 day of therapy Day 1
Secondary Placebo-adjusted change from baseline in PASP under normoxic and hypoxic conditions 8 hours after the fifth dose of study treatment 8 hours Day 5
Secondary Placebo-adjusted change from baseline in PASP under hypoxic conditions following 5 days of GSK1278863 Day 5
Secondary Clinical safety and tolerability data including AE reporting, ECGs, vital signs, physical exam findings and clinical laboratory values, including hematologic parameters Through-out the study Day 5
Secondary Plasma pharmacokinetics (AUC, Cmax, Tmax, T1/2, etc.) of GSK1278863 and its circulating metabolites (M2, M3, M4, M5, M6 and M13) Through-out the study Day 5
Secondary RV size, RV ejection fraction, severity of tricuspid regurgitation, right ventricular outflow tract acceleration time at all time points at which echocardiograms are obtained (as data permit) Exploratory outcomes; through-out the study Day 5
Secondary Biomarker/PD endpoints may include EPO, endothelin-1 and hepcidin or other markers of PHD or HIF activity, as data permit Exploratory outcomes; through-out the study Day 5
See also
  Status Clinical Trial Phase
Recruiting NCT05682326 - Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) Phase 3
Completed NCT03400033 - Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Phase 3
Completed NCT02879305 - Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Phase 3
Completed NCT02876835 - Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Phase 3
Terminated NCT02801162 - Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard N/A
Completed NCT02288637 - Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product N/A
Completed NCT00276224 - Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia N/A
Completed NCT00857077 - Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana N/A
Completed NCT06080555 - Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia Phase 1
Completed NCT01977573 - A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD) Phase 2
Completed NCT02243306 - Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis Phase 1
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00140517 - Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance N/A
Completed NCT03239522 - Absorption and Elimination of Radiolabeled Daprodustat Phase 1
Completed NCT01376232 - Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil) Phase 1
Completed NCT02019719 - Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Phase 2
Completed NCT02969655 - A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02637102 - The UK CAVIAR Study
Completed NCT01454752 - Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition N/A
Completed NCT01136850 - Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea Phase 3